{
  "cutoff": "2026-10-12",
  "note": "Selected publication milestones, not an exhaustive history or discovery priority claim.",
  "milestones": [
    {
      "pmid": "3928674",
      "year": "1985",
      "title": "Treatment of hot flashes with transdermal estradiol administration.",
      "doi": "10.1210/jcem-61-4-627",
      "url": "https://pubmed.ncbi.nlm.nih.gov/3928674/",
      "interpretation": "Transdermal estradiol dose experiments linked measured exposure to symptom suppression in a controlled short trial."
    },
    {
      "pmid": "9840563",
      "year": "1998",
      "title": "Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.",
      "doi": "10.1016/s0029-7844(98)00305-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9840563/",
      "interpretation": "PEPI compared systemic regimens and showed vasomotor relief without a matching generalized cognitive/affective benefit."
    },
    {
      "pmid": "11872200",
      "year": "2002",
      "title": "Estrogen raises the sweating threshold in postmenopausal women with hot flashes.",
      "doi": "10.1016/s0015-0282(01)03009-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11872200/",
      "interpretation": "A randomized laboratory experiment tested the predicted sweating-threshold response using physiological symptom recording."
    },
    {
      "pmid": "12117397",
      "year": "2002",
      "title": "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.",
      "doi": "10.1001/jama.288.3.321",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12117397/",
      "interpretation": "WHI combined-regimen prevention outcomes forced separation of symptom relief from chronic disease benefit and harm."
    },
    {
      "pmid": "12771112",
      "year": "2003",
      "title": "Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.",
      "doi": "10.1001/jama.289.20.2651",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12771112/",
      "interpretation": "WHIMS tested incident dementia in an older enrolled population rather than assuming symptom efficacy conferred brain protection."
    },
    {
      "pmid": "18987368",
      "year": "2008",
      "title": "Testosterone for low libido in postmenopausal women not taking estrogen.",
      "doi": "10.1056/NEJMoa0707302",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18987368/",
      "interpretation": "APHRODITE established an indication-specific testosterone counterexample: modest HSDD benefit without concomitant estrogen."
    },
    {
      "pmid": "24861828",
      "year": "2014",
      "title": "Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.",
      "doi": "10.1001/jamainternmed.2014.1891",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24861828/",
      "interpretation": "MsFLASH directly compared estradiol, venlafaxine and placebo for baseline bothersome vasomotor symptoms."
    },
    {
      "pmid": "24716847",
      "year": "2014",
      "title": "Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy.",
      "doi": "10.1111/cen.12459",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24716847/",
      "interpretation": "A selective verbal-learning testosterone signal remained bounded by null cognitive domains and general wellbeing."
    },
    {
      "pmid": "27028912",
      "year": "2016",
      "title": "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.",
      "doi": "10.1056/NEJMoa1505241",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27028912/",
      "interpretation": "ELITE showed why early-start surrogate vascular changes and hard disease prevention must be distinguished."
    },
    {
      "pmid": "29889748",
      "year": "2018",
      "title": "A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.",
      "doi": "10.1097/AOG.0000000000002645",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29889748/",
      "interpretation": "REPLENISH evaluated a defined oral estradiol/progesterone capsule with symptom and finite endometrial endpoints."
    },
    {
      "pmid": "38818888",
      "year": "2024",
      "title": "Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).",
      "doi": "10.1177/03000605241247684",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38818888/",
      "interpretation": "A tested fezolinetant regimen failed to outperform placebo in MOONLIGHTI, mapping a nonhormonal context limit."
    },
    {
      "pmid": "40920404",
      "year": "2025",
      "title": "Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.",
      "doi": "10.1001/jamainternmed.2025.4421",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40920404/",
      "interpretation": "OASIS3 expanded contemporary neurokinin-pathway symptom evidence while separating confirmatory and descriptive follow-up endpoints."
    }
  ],
  "gaps": [
    "The complete endocrine-to-thermoregulatory mediator sequence is not isolated by ordinary efficacy trials.",
    "Allocation-guess assessment and objective symptom sensing are incompletely integrated in large hormone trials.",
    "Long-term hard endpoints for contemporary transdermal estradiol/micronized progesterone begun near menopause need direct assessment rather than extrapolation from oral CEE/MPA or observational continuation.",
    "Physiological-dose testosterone requires replicated patient-important nonspecific cognition, fatigue and muscle-function endpoints; supraphysiologic dose signals do not establish ordinary replacement benefit.",
    "Rare breast, vascular and liver harms require formulation-specific long-term surveillance and cannot be excluded by small short trials."
  ],
  "decisive_experiment": "Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3."
}